Biofrontera (BFRI) Short-Term Debt to Capital

Biofrontera, Inc. - graphic logo of issuer BFRI

This chart on the GURU.Markets platform illustrates the price action of Biofrontera Inc. (BFRI), which currently stands at 0.09. Biofrontera Inc. (BFRI) dominates the skin light therapy niche, developing advanced LED systems and activation gels. High barriers to entry are secured by patents and FDA certification, while business stability is supported by the absence of political risks regarding shipments from Germany to the US.

biofrontera-us.com (BFRI) Ratio of Short-Term Indebtedness to Capital: for the period 07/04/2022 - 10/28/2026

Metric breakdowns and analytics for Biofrontera Inc (BFRI)

- price and consensus price forecast:
Stock Price Biofrontera Inc.|BFRI - Fair Value Consensus
- market capitalization data:
Market Capitalization Biofrontera, Inc.|BFRI - Enterprise Value
- book capitalization data:
Net Assets per Single Share Biofrontera|BFRI - Accounting Value of Company|Market Value to Book Value Ratio biofrontera-us.com|BFRI - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Biofrontera Inc.|BFRI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Biofrontera Inc.|BFRI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Biofrontera, Inc.
General company analysis:Biofrontera, BFRI
Brand item of biofrontera-us.com

Investors utilize this ratio to assess the debt load and the company's resilience to changes in borrowing costs. The metric compares short-term liabilities to equity, and the current short-term debt to equity value reflects the degree of financial leverage that Biofrontera Inc. (BFRI) can employ to modernize plants through the implementation of robotic packaging systems and AI control.

Competing companies

Krystal Corp (KRYS) - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Apogee Corp (APGE)|Short-Term Debt to Capital ARQT (Arcutis Biotherapeutics)|vcel.com - Short-Term Debt to Capital|Short-Term Debt to Equity Oruka Therapeutics (ORKA)|SMTI: Ratio of Short-Term Indebtedness to Capital|DBVT (dbv-technologies.com) - Short-Term Debt to Equity|Solesence (SLSN) - Short-Term Debt to Equity Ratio|DERM (Journey Medical Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital fortebiorx.com (FBRX)|Empro Group (EMPG) - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SLGL (Sol-Gel Technologies Ltd)|Short-Term Debt to Equity AXIL|Medicus Pharma Corp - Short-Term Debt to Capital Coefficient|Verrica - Short-Term Debt to Equity|HOTH - Short-Term Debt to Capital|vynetherapeutics.com - Short-Term Debt to Capital|SNOA (Sonoma Pharmaceuticals, Inc.) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Quoin Pharmaceuticals Ltd (QNRX)|Short-Term Debt to Capital Ratio Azitra Corporation|Short-Term Debt to Capital Dermata Therapeutics (DRMA)|Short-Term Debt to Equity elevaiskincare.com (ELAB)|Short-Term Debt to Capital RVNC